Home | Links | Contact Us | More About Intellectual Property | Bookmark
Search patents:
Home Gene Therapy Solid-phase-dispersion-of-quinolone-or-naphthyridonecarboxylic-acids

 Expression of recombinant glyoprotein B from herpes simplex virus
The nucleotide sequence and the amino acid sequence derived therefrom are provided for Herpes S...


 Enhancing agent for nerve growth factor production comprising a compound having a coumarin backbone or a compound having a 2-dimethyl chroman backbone
The invention claimed is: 1. A therapeutic agent or prophylactic agent for a disease requiring ...


 In vitro packaging of adeno-associated virus DNA
It is an object of the present invention to provide a method for packaging a DNA substrate in an in ...


 Recombinant viral vector system
The present invention relates to the in vitro synthesis of a novel 165 basepair fragment of DNA ...


 Modified adeno-associated virus vector capable of expression from a novel promoter
This invention provides an adeno-associated viral vector comprising the inverted terminal repeat ...


 Culturable mitochondrial cells with no nucleus, showing mitochondrial activity
OF THE INVENTION Hereinafter, the present invention will be described in detail. (1) Method of P...


 Antisense oligonucleotides inhibiting human bcl-2 gene expression
The invention provides oligodeoxynucleotides and methods for inhibiting growth of lymphoma or ...


 Process for the synthesis of oligomeric compounds
What is claimed is: 1. A method for the preparation of an oligomeric compound having a moiety of F...


 Process for oligonucleotide synthesis
OF THE PREFERRED EMBODIMENTS The present invention is directed to methods for linking a ...


 Derivatized oligonucleotides having improved uptake and other properties
OF THE INVENTION Antisense therapeutics can be practiced in a variety of organisms ranging from ...


 Solid phase dispersion of quinolone or naphthyridonecarboxylic acids

Details
Inventors: Cabrera, Francisco;
Assignee: Bayer HealthCare LLC (Tarrytown, NY)
Primary Examiner: Sheikh; Humera N.
Assistant Examiner:
Attorney, Agent or Firm: Pellegrino; Susan M.

The present invention relates to a solid dispersion of quinolone- or naphthyridonecarboxylic acids in an insoluble matrix representative of a shellac, and methods preparing and using the same in masking the taste and improving the uptake by animals.

DETAILED DESCRIPTION What is claimed is: 1.
A solid phase dispersion comprising a micronized quinolinecarboxylic acid or micronized naphthyridonecarboxylic acid in an insoluble matrix, wherein the insoluble matrix is shellac and wherein the particle size of the solid dispersion is about 20 to about 100 mesh size.
2.
The dispersion of claim 1, wherein quinolinecarboxylic acid or naphthyridonecarboxylic acid and the insoluble matrix are in a ratio of 1:0.
5 to 10.
3.
The dispersion of claim 2, wherein quinolinecarboxylic acid or naphthyridonecarboxylic acid and the insoluble matrix are in a ratio of 1:5.
4.
A method of preparing a solid dispersion of a quinolinecarboxylic acid or naphthyridonecarboxylic acid, comprising forming a hydrate of micronized quinolinecarboxylic acid or micronized naphthyridonecarboxylic acid, mixing the quinolinecarboxylic acid or naphthyridonecarboxylic acid with an insoluble matrix, wherein the soluble matrix is shellac, heating the mixture until it flows, and micronizing the mixture to reduce particle size, wherein said particle size is about 20 to about 100 mesh size.
5.
A feed formulation comprising feedstuff and the solid phase dispersion of claim 1.
6.
A process for improving animal uptake of quinolinecarboxylic acid or naphthyridonecarboxylic acid comprising orally administering to the animal a solid phase dispersion of claim 1 in an effective amount to mask the taste of the active agent.




Description:
FIELD OF THE INVENTION The present invention relates to the preparation of orally administrable formulations of quinolone- or naphthyridonecarboxylic acids and methods of making and using the same.
More specifically, the invention relates to quinolone- or naphthyridonecarboxylic acids in a solid phase dispersion, which masks their bitter taste.
BRIEF DESCRIPTION OF THE PRIOR ART Quinolonecarboxylic acids and their formulations are already known.
See, for example, EP-A (European Published Specification) 238 814.
Of particular interest here are formulations that are intended to mask the bitter taste of the active quinolone compounds



Related patents
  Peptide, process for its preparation and pharmaceutical composition containing same
We claim: 1. pGlu-Pro-Pro-Gly-Gly-Ser-Lys-Val-Ile-Leu-Phe. 2. A pharmaceutical composition for cell-growth stimulating action comprising an effective amount of the ...
  Stable pharmaceutical composition and method for its production
It is an object of the present invention to provide a stable pharmaceutical composition wherein the absorbability of a lipophilic drug which is insoluble or practically ...
  Pharmaceutical composition for treatment of adult respiratory distress syndrome containing human ANP
The present invention has been accomplished under these circumstances and has as an object providing a pharmaceutical composition effective against ARDS, more ...
  Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
OF THE PREFERRED EMBODIMENT The following standard abbreviations for the amino acid residues are used throughout the specification: Ala--alanine; Glu--glutamic acid; P...
  Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
The invention provides an isolated peptide that functionally mimics a binding site for a monoclonal antibody, the monoclonal antibody recognizing an epitope within the ...
  Adjuvant and vaccine compositions containing monophosphoryl lipid A
What is claimed: 1. A lyophilized composition comprising 0.2% up to 5% by weight 3-O-desacyl-4'-monophosphoryl lipid A, at least 70% by weight of sugar and 0% to about 30...
  Methods for preparation of vaccines against cancer
The present invention relates to methods for producing increased amounts of immunogenic material which can be used for prevention and treatment of cancer. The ...
  Human genes and gene expression products V
OF THE INVENTION The invention relates to polynucleotides comprising the disclosed nucleotide sequences, to full length cDNA, mRNA genomic sequences, and genes ...
  Haptotactic peprides
The invention claimed is: 1. An isolated haptotactic peptide of 20 amino acids consisting of the amino acid sequence as set forth in SEQ ID NO:1, characterized in that ...
  Hepatitis C virus inhibitors
OF THE INVENTION Stereochemical definitions and conventions used herein generally follow McGraw-Hill Dictionary of Chemical Terms, S. P. Parker, Ed., McGraw-Hill Book C...

0.024

Archive: All patents - Links

Copyright (c)2006 Eipa-patents.org - All rights reserved